93
Novel Biomarkers and Immunomodulating Therapies Targeting Cardiovascular Diseases Yao Mattisson, Ingrid 2019 Document Version: Publisher's PDF, also known as Version of record Link to publication Citation for published version (APA): Yao Mattisson, I. (2019). Novel Biomarkers and Immunomodulating Therapies Targeting Cardiovascular Diseases. Lund University: Faculty of Medicine. Total number of authors: 1 Creative Commons License: Unspecified General rights Unless other specific re-use rights are stated the following general rights apply: Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal Read more about Creative commons licenses: https://creativecommons.org/licenses/ Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Novel Biomarkers and Immunomodulating Therapies Targeting

  • Upload
    others

  • View
    6

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Novel Biomarkers and Immunomodulating Therapies Targeting

LUND UNIVERSITY

PO Box 117221 00 Lund+46 46-222 00 00

Novel Biomarkers and Immunomodulating Therapies Targeting CardiovascularDiseases

Yao Mattisson, Ingrid

2019

Document Version:Publisher's PDF, also known as Version of record

Link to publication

Citation for published version (APA):Yao Mattisson, I. (2019). Novel Biomarkers and Immunomodulating Therapies Targeting CardiovascularDiseases. Lund University: Faculty of Medicine.

Total number of authors:1

Creative Commons License:Unspecified

General rightsUnless other specific re-use rights are stated the following general rights apply:Copyright and moral rights for the publications made accessible in the public portal are retained by the authorsand/or other copyright owners and it is a condition of accessing publications that users recognise and abide by thelegal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private studyor research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: https://creativecommons.org/licenses/Take down policyIf you believe that this document breaches copyright please contact us providing details, and we will removeaccess to the work immediately and investigate your claim.

Page 2: Novel Biomarkers and Immunomodulating Therapies Targeting

Novel Biomarkers and Immunomodulating Therapies Targeting Cardiovascular DiseasesINGRID YAO MATTISSON

EXP. CARDIOVASC. RESEARCH | FACULTY OF MEDICINE | LUND UNIVERSITY

Page 3: Novel Biomarkers and Immunomodulating Therapies Targeting

Department of Clinicla Sciences, MalmöExperimental Cardiovascular Research

Lund University, Faculty of Medicine Doctoral Dissertation Series 2019:39

ISBN 978-91-7619-768-4 ISSN 1652-8220

INGRID YAO MATTISSON was born in Uppsala and moved shortly thereafter to Skåne. She was introduced early into the field of medical research and even before starting her own academic studies she was experienced in taking care of laboratory animals. Ingrid studied molecular biology at Lund University and did several projects after that within the field of Vascular Physiology before she started her PhD studies at the Cardiovascular Research Unit in 2015.

Ingrid successfully continued to work on newly established projects within the field of cardiovascular disease and systemic lupus erythematosus (SLE). It is always with great enthusiasm, ambition and dedication to her work that she undertakes different assignments.

In parallel to research Ingrid has a passion for her Icelandic horses, a valuable contrast to “research life”. In this thesis, Ingrid describes her research findings in a clear and personal way, showing the great amount of knowledge she has gained over the last years.

-Maria Wigren, co-supervisor

9789176

197684

Page 4: Novel Biomarkers and Immunomodulating Therapies Targeting

Faculty opponent

Page 5: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 6: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 7: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 8: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 9: Novel Biomarkers and Immunomodulating Therapies Targeting

in vitro

Page 10: Novel Biomarkers and Immunomodulating Therapies Targeting

EbioMedicine

Atherosclerosis

Manuscript

in vitro

Vascular Pharmacology,

Page 11: Novel Biomarkers and Immunomodulating Therapies Targeting

Arteriscler Thromb Vasc Biol,

Stroke

Sci Rep.,

PLoS One.

J Intern Med

Arterioscler Thromb Vasc Biol,

J Am Heart Assoc. 19;8(4):e009874,

Page 12: Novel Biomarkers and Immunomodulating Therapies Targeting

Circulation (ePub ahead of print)

Submitted to ebioMedicine

in vitroSubmitted to Phytoscience

Submitted to Stroke

Page 13: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 14: Novel Biomarkers and Immunomodulating Therapies Targeting

γ γ

Page 15: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 16: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 17: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 18: Novel Biomarkers and Immunomodulating Therapies Targeting

in vivo

Page 19: Novel Biomarkers and Immunomodulating Therapies Targeting

αβ

Page 20: Novel Biomarkers and Immunomodulating Therapies Targeting

α

Page 21: Novel Biomarkers and Immunomodulating Therapies Targeting

Costimulation

Page 22: Novel Biomarkers and Immunomodulating Therapies Targeting

γ γ

γ

Page 23: Novel Biomarkers and Immunomodulating Therapies Targeting

β

Page 24: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 25: Novel Biomarkers and Immunomodulating Therapies Targeting

γα ε

Page 26: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 27: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 28: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 29: Novel Biomarkers and Immunomodulating Therapies Targeting

Soluble death receptors

Page 30: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 31: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 32: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 33: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 34: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 35: Novel Biomarkers and Immunomodulating Therapies Targeting

Th1 cells in atherosclerosis

γ

Th2 cells in atherosclerosis

Th17 cells in atherosclerosis

in vivo

Regulatory T cells in atherosclerosis

Page 36: Novel Biomarkers and Immunomodulating Therapies Targeting

B cells in atherosclerosis

Page 37: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 38: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 39: Novel Biomarkers and Immunomodulating Therapies Targeting

“probably not an autoimmune disease in the classical sense but rather a state of local immune dysfunction resulting in an imbalance between naturally occurring autoimmunity and the regulatory immune cells that should control this autoimmunity”153

Page 40: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 41: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 42: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 43: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 44: Novel Biomarkers and Immunomodulating Therapies Targeting

Oral tolerance induction with ApoB100 peptides

ββ

Page 45: Novel Biomarkers and Immunomodulating Therapies Targeting

in vitro

β

Page 46: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 47: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 48: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 49: Novel Biomarkers and Immunomodulating Therapies Targeting

lpr

Page 50: Novel Biomarkers and Immunomodulating Therapies Targeting

gld

Page 51: Novel Biomarkers and Immunomodulating Therapies Targeting

in vitro

Page 52: Novel Biomarkers and Immunomodulating Therapies Targeting

ββ in vitro

.

Page 53: Novel Biomarkers and Immunomodulating Therapies Targeting

Conclusion

Page 54: Novel Biomarkers and Immunomodulating Therapies Targeting

in vitro

Page 55: Novel Biomarkers and Immunomodulating Therapies Targeting

β

Page 56: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 57: Novel Biomarkers and Immunomodulating Therapies Targeting

Conclusion

Page 58: Novel Biomarkers and Immunomodulating Therapies Targeting

in vitro

Page 59: Novel Biomarkers and Immunomodulating Therapies Targeting

μ in vitro

Page 60: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 61: Novel Biomarkers and Immunomodulating Therapies Targeting

Conclusion

in vitro

Page 62: Novel Biomarkers and Immunomodulating Therapies Targeting

in vitro

Page 63: Novel Biomarkers and Immunomodulating Therapies Targeting

β

lpr

Page 64: Novel Biomarkers and Immunomodulating Therapies Targeting

in vitro

β β

in vitroin vivo

Page 65: Novel Biomarkers and Immunomodulating Therapies Targeting

in vitro β

Conclusion in vitro

in vivo

βin vitro in vivo

Page 66: Novel Biomarkers and Immunomodulating Therapies Targeting

in vivo

in vivo

Page 67: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 68: Novel Biomarkers and Immunomodulating Therapies Targeting

Future perspectives

Page 69: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 70: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 71: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 72: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 73: Novel Biomarkers and Immunomodulating Therapies Targeting
Page 74: Novel Biomarkers and Immunomodulating Therapies Targeting

in vivo

Page 75: Novel Biomarkers and Immunomodulating Therapies Targeting

en face

in vivo

Page 76: Novel Biomarkers and Immunomodulating Therapies Targeting

in vivo

Page 77: Novel Biomarkers and Immunomodulating Therapies Targeting

Lancet

J Glob Infect Dis

J Allergy Clin Immunol

et al. J Immunol

Annu Rev Immunol

Nat Immunol

Front Immunol

Immunol Today

Nat Immunol et al.

J Immunol

Vaccines (Basel)

Cold Spring Harb Symp Quant BiolNat

Rev Immunol

Nature

ILAR J

Page 78: Novel Biomarkers and Immunomodulating Therapies Targeting

J Exp Med

Nat Rev Immunol

Nat Rev Immunol

Immunity

Eur J Pharmacol

et al.Cell

et al.Proc Natl Acad Sci U S A

Arterioscler Thromb

et al. Circ Res

Nat Rev Immunol

Front Immunol

et al.Immunity

et al.EMBO Mol Med

Autoimmun Rev

et al.J Immunol

et al.

Diabetes

Page 79: Novel Biomarkers and Immunomodulating Therapies Targeting

et al.Arthritis Rheum

et al.Front

Physiol et al. Dis

Markers et al.

N Engl J Med

et al.N Engl J Med

et al.Clin Immunol

Front Immunol

et al.Cell Mol Life Sci

et al.J Exp Med

J Immunol

Nature

Curr Opin Immunol

Nat Immunol

Nat Rev Immunol et al.

J Allergy Clin Immunol

Arthritis Rheum

Page 80: Novel Biomarkers and Immunomodulating Therapies Targeting

et al.J Exp Med

Eur J Immunol

J Immunol

Keio J Med

Journal of Cell Biology

Annu Rev Immunol

Circ Res

Nat Rev Immunol

Microbiol Spectr

J Allergy Clin Immunol

Immunol Rev

Journal of Clinical Investigation

Autoimmun Rev

Nat Rev ImmunolAnnu Rev

Pharmacol ToxicolAm J Pathol

Br J CancerCell biology. A laboratory

handbook

Page 81: Novel Biomarkers and Immunomodulating Therapies Targeting

et al.Cell Death Differ

Oncogene

Nat Rev Mol Cell BiolScience

Cold Spring Harb Perspect Biol

J Biol Chem et al.

J Clin Invest

Cell Immunol

J Leukoc Biol

PLoS One et al.

Circulation

Ann N Y Acad Sci

N Engl J Med

Circ Res

Exp Clin Cardiol

Acta Chir Belg

Page 82: Novel Biomarkers and Immunomodulating Therapies Targeting

NatureCirc Res

Arterioscler Thromb Vasc Biol

Immunity

N Engl J Med

Circulation et al.

J Biol ChemNature

immunologyNew England Journal

of MedicineNew England Journal of

MedicineCell

Arterioscler Thromb Vasc Biol

Arterioscler Thromb Vasc Biol

Ann N Y Acad Sci

Clin Dev Immunol

Arteriosclerosis et al.

Circ Res

J Clin Invest

Page 83: Novel Biomarkers and Immunomodulating Therapies Targeting

Circulation et al. Free Radic Biol Med

Curr Opin Lipidol

J Autoimmun

Circulation et al.

Arthritis Rheum

et al.Arterioscler Thromb

Vasc Biol

J Immunol

et al.Arterioscler

Thromb Vasc Biol et al. J

Clin Invest et al.

Arterioscler Thromb Vasc Biol

Am J Pathol

et al.Proc Natl Acad Sci U S A

et al.Circulation

et al.J Am Coll Cardiol

et al.J Clin Invest

Page 84: Novel Biomarkers and Immunomodulating Therapies Targeting

et al.Cardiovasc Res

et al.Immunity

et al.Nat Commun

et al.PLoS One

et al.Arterioscler Thromb Vasc Biol

et al.

Eur Heart J et al.

J Immunol

et al.Circulation

et al.Arterioscler Thromb Vasc Biol

Nat Rev Immunol et al.

Mol Med

et al.Arterioscler Thromb Vasc Biol

J Clin Invest

et al.J Immunol

et al.J Exp Med

World J Surg

Page 85: Novel Biomarkers and Immunomodulating Therapies Targeting

et al.Journal of Clinical

Endocrinology and Metabolism et al.

Diabetes et al.

N Engl J Med et al.

Diabetes Care

PLoS Comput Biol

et al. Sci Rep

J Nutr Biochem

et al.Diabetes

Cardiovasc Diabetol

Am J Manag Care

et al.

J Intern Med et al.

Diabetologia

Nat Immunol

Nature

Acta Biomed

Annu Rev Med

Page 86: Novel Biomarkers and Immunomodulating Therapies Targeting

J Autoimmun

J Intern Med

Front Immunol

Proc Natl Acad Sci U S A et al.

Proc Natl Acad Sci U S A

Atherosclerosis

et al.Arterioscler Thromb

et al.

Arterioscler Thromb

Arterioscler Thromb Vasc Biol et al.

Free Radic Biol Med

et al.Clin Exp Immunol

et al.Arterioscler Thromb Vasc Biol

et al.Stroke

et al.

Atherosclerosis

Consult Pharm

Page 87: Novel Biomarkers and Immunomodulating Therapies Targeting

J Intern Med

J Chronic Dis

Autoimmun Rev

et al.N Engl J Med

et al.Arthritis Rheum

JAMA et al.

Arthritis Rheum

et al.Rheumatology (Oxford)

Nat Rev Rheumatol

Clin Immunol Immunopathol et al.

Arthritis Res Ther et al.

Atherosclerosis

et al.Lupus

Ann N Y Acad Sci

Page 88: Novel Biomarkers and Immunomodulating Therapies Targeting

et al.

Clin Exp Immunol

J Am Coll Cardiol

Curr Pharm Des

Vaccines (Basel)

Immunol Cell Biol

Scand J Immunol

F1000 Med Rep

et al.

Circulation

Immunol Res

et al.

Atherosclerosis

Annual Review of Biochemistry

Proc Natl Acad Sci U S A et al.

Arterioscler Thromb Vasc Biol

et al.Arterioscler Thromb Vasc Biol

J Intern Med

Page 89: Novel Biomarkers and Immunomodulating Therapies Targeting

et al.Dev Biol Stand

J Immunol

Proc Natl Acad Sci U S A

et al.

Arterioscler Thromb Vasc Biol

J Immunol et al.

Circulation

et al.

J Am Coll Cardiol et al.

Atherosclerosis

JAMA et al.

Atherosclerosis et al.

JACC Cardiovasc Imaging

et al.N Engl J Med

et al.N Engl J Med

Ther Adv Musculoskelet Dis

Page 90: Novel Biomarkers and Immunomodulating Therapies Targeting

Basic Clin Pharmacol Toxicol

Autoimmun Rev

J Intern Med et al.

Arthritis Rheum

Atherosclerosis

Adv Immunol et al.

J Exp MedNat Rev Nephrol

Epidemiology

N Engl J Med

et al.Arterioscler Thromb Vasc Biol

Semin Cell Dev Biol

Lupus et al.

Nat Med

et al.Arthritis

Rheum

et al.J Exp Med

Page 91: Novel Biomarkers and Immunomodulating Therapies Targeting

Nat Med

Arterioscler Thromb Vasc Biol

J Clin Rheumatol

Neth J Med

et al.Clin Diagn Lab Immunol

Curr Opin Rheumatol

J Clin Pathol

et al.Mol Metab

et al.J Biol Chem

J Clin Invest et al.

Exp Hematol et al. Curr Opin Lipidol

et al.Nat Med

et al.Arterioscler

Thromb Vasc Biol et al.

Arterioscler Thromb Vasc Biol

Page 92: Novel Biomarkers and Immunomodulating Therapies Targeting

J Immunol

et al.J Immunol

Ann Rheum Dis

Adv Immunol

et al.J Intern Med

et al. Adv Drug Deliv Rev

Braz J Med Biol Res

Cell

et al.Front Microbiol

Curr Opin Lipidol

Clin Chem

Nat Rev Immunol et al.

N Engl J Med

Page 93: Novel Biomarkers and Immunomodulating Therapies Targeting